Psychiatry and Neurology, Neurology · Teaneck, NJ
NPI
1245314806
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1 Degraw Ave Ste B
Teaneck, NJ, 07666
Phone (201) 855-8300
Groups this clinician bills Medicare through
Medicare paid, 2024
$155K
13,208 services
Medicare patients, 2024
264
Average age 75
Drug cost, 2024
$2.1M
2,540 prescriptions
Company payments, 2025
$7,985
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Charles F Asta was code J0585 (injection, onabotulinumtoxina, 1 unit), 7,245 times for 11 patients. In total Charles F Asta billed 13,208 services in 29 codes, and Medicare paid $155K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-07-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 7,245 | 11 | $4.97 | $36K |
| 99214 Office E&M - Established | Office | 512 | 203 | $100.48 | $51K |
| 99204 Office E&M - New | Office | 62 | 62 | $128.77 | $7,983 |
| 99213 Office E&M - Established | Office | 52 | 40 | $68.04 | $3,538 |
| 99215 Office E&M - Established | Office | 49 | 40 | $145.57 | $7,133 |
| 64615 Musculoskeletal | Office | 38 | 13 | $127.88 | $4,860 |
| 96136 Behavioral Health Services | Office | 27 | 27 | $33.35 | $900 |
| 96116 Behavioral Health Services | Office | 27 | 27 | $76.57 | $2,067 |
| 96132 Behavioral Health Services | Office | 25 | 25 | $109.63 | $2,741 |
| 96133 Behavioral Health Services | Office | 25 | 25 | $83.16 | $2,079 |
| 99205 Office E&M - New | Office | 13 | 13 | $169.96 | $2,210 |
| 95700 Neurologic | Office | 12 | 12 | $203.15 | $2,438 |
By year: 2022 $149K for 11,372 services; 2023 $158K for 11,710 services; 2024 $155K for 13,208 services.
Medicare prescription drug claims, 2024
In 2024, the drug Charles F Asta prescribed most often to Medicare patients was Memantine Hcl Er (Memantine Hcl), with 302 prescriptions and refills. In total Charles F Asta wrote 2,540 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Memantine Hcl Er Memantine Hcl | 302 | 569 | 70 | $28K |
| Donepezil Hcl Generic | 137 | 351 | 43 | $1,931 |
| Namzaric Memantine Hcl/Donepezil Hcl | 124 | 250 | 30 | $144K |
| Carbidopa-Levodopa Carbidopa/Levodopa | 102 | 254 | 27 | $2,845 |
| Gabapentin Generic | 98 | 224 | 31 | $1,768 |
| Topiramate Generic | 83 | 190 | 21 | $828 |
| Escitalopram Oxalate Generic | 83 | 224 | 25 | $1,366 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 68 | 68 | Under 11 | $1,868 |
| Quetiapine Fumarate Generic | 66 | 164 | 15 | $3,430 |
| Clonazepam Generic | 64 | 110 | 18 | $480 |
| Ropinirole Hcl Generic | 60 | 90 | Under 11 | $592 |
| Pregabalin Generic | 52 | 106 | 14 | $2,070 |
| Memantine Hcl Generic | 51 | 117 | 13 | $1,588 |
| Qulipta Atogepant | 48 | 48 | Under 11 | $50K |
| Ubrelvy Ubrogepant | 48 | 48 | Under 11 | $66K |
Brand drugs: - claims; generic drugs: 1,880 claims; opioid claims: 57.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Charles F Asta $7,985 ($7,985 in general payments such as food, travel and fees) from 34 companies. The largest payer was Abbvie Inc. with $4,613.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 34 | $4,613 |
| Pfizer Inc. PFE | 38 | $420 |
| Lundbeck LLC | 17 | $329 |
| Teva Pharmaceuticals USA, Inc. TEVA | 14 | $278 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $235 |
| Amneal Pharmaceuticals LLC AMRX | 14 | $226 |
| Argenx US, Inc. ARGX | 13 | $188 |
| Amgen Inc. AMGN | 5 | $182 |
| Axsome Therapeutics, Inc. AXSM | 11 | $178 |
| Neurocrine BioSciences, Inc. NBIX | 7 | $126 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.